Robenacoxib
Based on 1 Customer Validation
Robenacoxib is a nonsteroidal anti-inflammatory and analgesic agent. Robenacoxib is a selective COX-2 inhibitor.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98.08%
- No. CAS: 220991-32-2
- Fòrmula: C16H13F4NO2
- Peso molecular:327.27
-
Almacenamiento:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-B0386
Flunixin meglumineCOX Inhibitor -
HY-100516
CimicoxibCOX-2 Inhibitor -
HY-115866
COX-2-IN-6COX Inhibitor -
HY-B0493
Niflumic acidChloride Channel/COX Inhibitor -
HY-118078R
Robenacoxib (Standard)COX-2 Inhibitor -
HY-100516R
Cimicoxib (Standard)COX-2 Inhibitor -
HY-B0578A
Loxoprofen sodiumAnti-Inflammatory Agent -
HY-B1452
LicofeloneCOX/5-LOX Inhibitor -
HY-B0493R
Niflumic acid (Standard)Chloride Channel/COX Inhibitor -
HY-112731
TFAPCOX-1 Inhibitor -
HY-B0386R
Flunixin meglumine (Standard)COX Inhibitor -
HY-103387
DuP-697COX-2 Inhibitor
Actividad biológica
Descripciòn
Chemical Information
-
No. CAS 220991-32-2
-
Appearance Solid
-
Peso molecular 327.27
-
Fòrmula C16H13F4NO2
-
Color Off-white to light yellow
-
SMILES
O=C(CC1=CC(CC)=CC=C1NC2=C(C(F)=CC(F)=C2F)F)O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvente y solubilidad
In Vitro:
DMSO : 125 mg/mL (381.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocolo
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureza y Documentación
-
Ficha de datos (269 KB)
-
SDS (701 KB)
- English - EN (701 KB)
- Français - FR (701 KB)
- Deutsch - DE (701 KB)
- Norwegian - NO (701 KB)
- Español - ES (701 KB)
- Swedish - SV (701 KB)
- Italian - IT (701 KB)
- Korean - KR (701 KB)
- Portuguese - PT (701 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Kongara K, et al. Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy. Vet Med (Auckl). 2018 Aug 15;9:53-61. [Content Brief]
[2]. Schmid VB, et al. Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in dog. J Vet Pharmacol Ther. 2010 Apr;33(2):118-31. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0556 mL | 15.2779 mL | 30.5558 mL | 76.3895 mL |
| 5 mM | 0.6111 mL | 3.0556 mL | 6.1112 mL | 15.2779 mL | |
| 10 mM | 0.3056 mL | 1.5278 mL | 3.0556 mL | 7.6390 mL | |
| 15 mM | 0.2037 mL | 1.0185 mL | 2.0371 mL | 5.0926 mL | |
| 20 mM | 0.1528 mL | 0.7639 mL | 1.5278 mL | 3.8195 mL | |
| 25 mM | 0.1222 mL | 0.6111 mL | 1.2222 mL | 3.0556 mL | |
| 30 mM | 0.1019 mL | 0.5093 mL | 1.0185 mL | 2.5463 mL | |
| 40 mM | 0.0764 mL | 0.3819 mL | 0.7639 mL | 1.9097 mL | |
| 50 mM | 0.0611 mL | 0.3056 mL | 0.6111 mL | 1.5278 mL | |
| 60 mM | 0.0509 mL | 0.2546 mL | 0.5093 mL | 1.2732 mL | |
| 80 mM | 0.0382 mL | 0.1910 mL | 0.3819 mL | 0.9549 mL | |
| 100 mM | 0.0306 mL | 0.1528 mL | 0.3056 mL | 0.7639 mL |
Robenacoxib Related Classifications
HY-118078 Related Classifications
Powered by Bioz